KDM6B

Company progressing with plans to focus on its RNA business Advancing discussions for divestiture or spin-off of legacy assets, including BentrioTM and AM-125 nasal sprays Bentrio revenues were $1.3 million in first half of 2022 HAMILTON, Bermuda, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and key developments in its business. “We continue to be on track with our plan to refocus the Company around our exciting RNA delivery platform and to divest or spin off our legacy business to unlock the intrinsic value of our assets,” commented Thomas Meyer, the Company’s founder, CEO and Chairman. “Over the past few months, we made great progress in raising awareness of our patented OligoPhore / SemaPhore technology for efficient and safe RNA delivery to extrahepatic target tissues. “In addition, we reached important milestones with our nasal spray programs, Bentrio and AM-125, obtaining positive study data for both as well as regulatory clearance for Bentrio in the US and elsewhere. We are making good progress in our efforts to partner both programs, on which we have spent approximately $15 million and $18 million, respectively, to date.” Altamira expects to report its first-half 2022 financial results in early October 2022. Preliminary figures show that the Company recorded revenues related to Bentrio of $1.3 million during that period. LeveragingBentrio’s commercial potential in US and Europe through partnering As previously announced, Altamira’s strategy is to commercialize Bentrio globally through well-established OTC consumer health companies with a strong footprint in the respiratory health market, respectively the “allergy” and “cough and cold” categories. While the Company has already established distribution agreements with partners covering most of the important Asian markets except Japan, and the Middle East, the Company’s current partnering activities are focusing on the US, EU and other key international markets. Since receiving 510(k) clearance from the US Food and Drug Administration (FDA) for marketing Bentrio Allergy Blocker, Altamira has advanced partnering discussions with a number of interested parties in a structured process. In this context, the Company has suspended preparations for launching the product in the US on its own as well as major market initiatives in Europe. The US and Europe together represent the largest OTC markets worldwide by far. Major potential in allergy management… One of the key indications for Bentrio is the treatment of mild to moderate allergic rhinitis. In the US, 7.8% of people over 18 have hay fever,1 and the market for OTC allergy medicines was $4 billion in 2020.2 Traditionally, allergy management has been based on treatment with antihistamine or corticosteroid drugs and the use of decongestants to address nasal inflammation and the classic symptoms of nasal congestion, sneezing, nasal itching, and rhinorrhea. Among drug-free options, which have been growing in importance, saline nasal sprays are used for rinsing allergen particles off the nasal cavity. Bentrio as a drug-free and preservative-free nasal spray is designed to protect allergy sufferers by forming a mucous-like gel barrier that coats the nasal membranes for several hours, trapping inhaled allergens within the nasal cavity and helping with their clearance via the digestive tract. Bentrio’s protective effects have already been demonstrated clinically with controlled exposure to house dust mites and grass pollen in allergen challenge chambers for 3 to 4 hours. A larger clinical trial comparing Bentrio with a seawater nasal spray (the “NASAR” study) in Australia under “everyday conditions” over 14 days was started in 2021. Positive interim safety and efficacy data from the trial helped to support the successful 510(k) application to the FDA. NASAR is expected to resume enrollment with the upcoming start of the allergy season and to complete the enrollment target of 100 patients for a read-out in Q1 2023. … and in viral infection prevention and treatment The second key indication for Bentrio is the protection against airborne viral particles. COVID-19 dramatically raised peoples’ awareness of the risk of viral infections and has created a heightened interest in, and demand for, protection. Human rhinovirus (HRV) is the most common cause of upper respiratory tract infection, and influenza resulted in 9-45 million illnesses, 140,000-810,000 hospitalizations and 12,000-61,000 deaths annually since 2010.3 US revenues for cold and cough remedies in 2021 were more than $12 billion.4 Bentrio has been successfully tested on human nasal epithelium cells for protection against SARS-CoV-2, H1N1 influenza and, most recently, HRV. Bentrio’s mode of action is the same regardless of whether it shall provide a barrier against airborne virus or allergen particles. Altamira considers that the spray can also help to reduce the viral load in the nose and the risk of viral infection. However, certain countries and regions require specifically clinical performance data to clear Bentrio for this indication, in particular related to COVID-19. In this context, the Company recently stopped marketing Bentrio in the viral infection indication in the EU and Switzerland and will re-introduce the product in the coming weeks with a labeling for allergy only. COVAMID is a randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and efficacy of Bentrio in the treatment of acute COVID-19. It began enrolling patients in March 2022. Following a blinded interim analysis, Altamira recently announced that the trial will add 24 patients bringing the total to 160, with top-line data expected in Q4 2022. The Company expects the trial to be essential for supporting its plans to expand Bentrio’s product label to include viral infections in those countries and regions requesting such data. AM-125 moving towards IND filing In June 2022, the Company announced key results from its TRAVERS phase 2 trial with AM-125, a nasal spray with betahistine as active ingredient for the treatment of vertigo. The trial enrolled a total of 124 patients who suffered from acute vestibular syndrome (AVS) following surgery for the removal of a tumor growing behind the inner ear. TRAVERS demonstrated good safety and tolerability of AM-125 at doses up to 20 mg administered three times daily for four weeks. Further, administration of AM-125 resulted in a dose- and time-dependent improvement in balance and vestibular function. On the primary efficacy endpoint, the improvement in the "Tandem Romberg" balance test, the trial showed a statistically significant increase in the time to failure (i.e. for how long balance could be maintained) for the 20 mg dose over placebo. TRAVERS thus served as proof of concept for AM-125 acting as a vestibular stimulant and helping patients to ‘get back on their feet’ more quickly. Following further analyses of the TRAVERS outcomes, the study team has been drafting an article for publication in a scientific journal. Meanwhile, the Company has been working to move the AM-125 development program forward. Altamira is planning to Investigational New Drug (IND) application with the FDA in Q4 2022, which will include the protocol for the next clinical trial with AM-125. Benefitting from its intranasal administration route, AM-125 can achieve significantly higher betahistine concentrations in blood plasma than those obtained with the currently available tablets for oral administration. Globally, there has been a dearth of innovation for treating vertigo for decades. In the context of its strategic repositioning, Altamira has initiated partnering discussions on AM-125 with a number of interested parties. Increasing recognition of our RNA delivery platform Within its new RNA business, Altamira has continued to make great progress in development and in building awareness around its patented peptide-based platforms for RNA delivery to extrahepatic tissues. The Company recently announced the launch of AM-411 for the treatment of rheumatoid arthritis (RA), the second largest therapeutic area after oncology. This second program follows AM-401 for the treatment of KRAS-driven tumors and is built on its patented OligoPhore™ delivery platform and siRNA targeting NF-kB (p65), a key checkpoint in RA inflammation. AM-411 has already been shown to potently suppress early inflammatory arthritis in a collagen antibody-induced arthritis mouse model.5 The Company intends to develop both AM-401 and AM-411 with the objective of out-licensing the drug products at a later stage. Altamira’s RNA delivery platforms OligoPhore / SemaPhore™ are increasingly being recognized for their ability to deliver RNA payloads to tissues outside the liver which are challenging to reach for currently available technologies such as lipid nanoparticles (LNPs). Recently, two publications in peer-reviewed journals by independent research groups presented fresh evidence for the technology’s effects and comparative advantages in areas of great unmet medical need. A study by a Korean group highlighted the benefits of cell-penetrating peptides over LNPs. In addition, this study compared eight such peptides in their ability to mediate cellular uptake and promote protein expression of mRNA in cancer cells and found Altamira’s SemaPhore to be the most efficient among the technologies tested.6 Another study by a Chinese group showed a remarkably mitigated severity of joint degeneration in a mouse model of osteoarthritis after treatment with OligoPhore-based nanoparticles comprising siRNA targeting the JMJD3 gene.7 In order to further increase awareness among research scientists and drug developers, Altamira will present its technology in a series of specialized conferences in the coming months. In addition, the Company will continue to expand its business development efforts for selective out-licensing of its delivery platforms as it becomes an RNA-focused company. About Altamira Therapeutics Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne allergens and, where approved, viruses (Bentrio™; commercial) or for the treatment of vertigo (AM-125; post Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: Forward-Looking Statements This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. CONTACT Investors@altamiratherapeutics.com 800-460-0183 1 National Ambulatory Medical Care Survey 2 3 Centers for Disease Control and Prevention 4 5 Zhou et al. (2014), Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis, J Clin Invest 124(10):4363-74. 6 Kim et al. (2022), The potential of cell-penetrating peptides for mRNA delivery to cancer cells, Pharmaceutics 14(6), 1271. 7 Jin et al. (2022), Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1, Int J Oral Sci 14:34.

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint degeneration in animal modelHAMILTON, BERMUDA , July 28, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the scientific journal International Journal of Oral Science titled, "Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1" that covers an independently funded study evaluating novel treatment approaches for osteoarthritis (OA) conducted by a Shanghai-based research group. Study highlights The study used different approaches to downregulate the Jumonji domain-containing protein D3 (JMJD3) gene to assess whether this strategy would be beneficial for the treatment of OA. Nanoparticles comprising a siRNA targeting the JMJD3 gene, and Altamira’s peptide-based OligoPhore delivery platform (also known as “p5RHH”), were used to locally downregulate the expression of JMJD3 in a mouse model of OA. The study authors observed that, “the severity of joint degeneration was remarkably mitigated” thanks to administration of the nanoparticles and highlighted their “advantage of specifically targeting inflammation in the joint without off-target toxicities.” They propose JMJD3 inhibition – based on the OligoPhore platform – as an “innovative epigenetic therapy approach for joint diseases.” In their study, the authors pursued an epigenetic-based therapeutic approach (i.e. targeting gene regulation) to mitigate cartilage inflammation and damage in a murine model of osteoarthritis. OligoPhore was used to formulate siRNA polyplexes that inhibited chondrocyte production of a histone demethylase, JMJD3, in response to joint damage. JMJD3 is upregulated in joint injury and drives other inflammatory pathways to elicit further damage and chondrocyte programmed cell death. Injection of 2 weekly doses of OligoPhore-siRNA into the affected joint over 8 weeks significantly attenuated inflammation and preserved cartilage viability and integrity. CSO comments "The study's results confirm prior findings reporting the benefit of RNA therapeutics based on our nanoparticle delivery platform in models in rheumatoid arthritis and, now, osteoarthritis," commented Samuel Wickline, MD, Altamira Therapeutics’ Chief Scientific Officer." One of the key features of OligoPhore is the targeted delivery to inflamed tissues, making it particularly well suited for the treatment of arthritis with oligonucleotides, both in terms of efficacy and safety. "Osteoarthritis can have a significantly detrimental impact on the well-being and quality of life of patients, often over many years or even decades, yet there is still no disease-modifying treatment available,” Dr. Wickline added. “While our AM-411 program is targeting rheumatoid arthritis, we envision extending its potential use to osteoarthritis as well." Earlier this week, the Company announced the initiation of AM-411, a development program based on its proprietary OligoPhore delivery platform and siRNA targeting NF-κB, for a novel generation of rheumatoid arthritis (RA) therapeutics. Osteoarthritis to become one of the most prevalent diseases in the coming decades Osteoarthritis is a degenerative joint disease that can affect the many tissues of the joint.1 It can degrade cartilage, change bone shape and cause inflammation, resulting in pain, stiffness and loss of mobility. OA can affect any joint, but typically affects hands, knees, hips, lower back and neck. Its signs and symptoms typically show up more often in individuals over age 50, but OA can affect much younger people, too, especially those who have had a prior joint injury. There is no cure for OA, but there are ways to manage OA to minimize pain, continue physical activities, maintain a good quality of life and remain mobile. OA is by far the most common form of arthritis, affecting more than 32.5 million adults in the United States, according to the Centers for Disease Control and Prevention. The global prevalence of OA is increasing and the burden of the disease will rise.2 The medical cost of osteoarthritis in various high-income countries has been estimated to account for between 1% and 2.5% of the gross domestic product of these countries, with hip and knee joint replacements representing the major proportion of these health-care costs. About International Journal of Oral Science The International Journal of Oral Science seeks to publish all aspects of oral science and interdisciplinary fields, including basic, applied and clinical research. The Journal publishes peer-reviewed articles that describe new research results and review articles that provide succinct summaries of an area in oral science. The International Journal of Oral Science is published by Springer Nature. For more information, visit: https://www-nature-com.libproxy1.nus.edu.sg/ijos/aims About OligoPhore OligoPhore is a versatile platform for safe and effective delivery of oligonucleotides such as siRNA (small interfering ribonucleic acid) into target cells. It is based on a proprietary 21-amino acid peptide that can engage any type of RNA in rapid self-assembly into a polyplex. The polyplex has a size, charge, and other physical features that allow it to escape hepatic clearance and thus to reach other target tissues than the liver. OligoPhore protects the RNA payload from degradation in the circulation and allows for rapid cellular uptake, while enabling pH-dependent nucleotide endosomal escape and cytoplasmic delivery. Effective delivery and positive treatment outcomes have been demonstrated in more than 10 murine models of disease for targets in the NF-κB family, various members of the ETS transcription factor family, and targets in the JNK and TAM pathways. About Altamira Therapeutics Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne allergens and, where approved, viruses (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/ Forward-Looking Statements This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. CONTACT Investors@altamiratherapeutics.com 800-460-0183 1 https://www.arthritis.org/diseases/osteoarthritis 2 Hunter DJ & Bierma-Zeinstra S (2019), Osteoarthritis, Lancet 393:1745-59.

– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided an operational update. “We made considerable progress throughout the first half of 2021, highlighted by the acquisition of Oncoceutics, the initiation of the Phase 3 DASH AML trial, and the FDA approval of TEMBEXA as a medical countermeasure for smallpox. This approval is an important milestone as it marks Chimerix’s first FDA approved drug and is the first smallpox antiviral approved for all age groups, including infants, with an available oral solution for patients who have difficulty swallowing,” said Mike Sherman, Chief Executive Officer of Chimerix. “Looking ahead to the balance of the year, we expect to report the efficacy analysis by BICR for ONC201 and complete TEMBEXA manufacturing to support U.S. national preparedness.” Recent Highlights TEMBEXA for Smallpox In June, the FDA granted TEMBEXA tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients and is the first and only smallpox therapy approved for neonates. The oral suspension formulation is particularly important for patients who have difficulty swallowing due to age or medical status. TEMBEXA potentially fills an important role as a treatment countermeasure to smallpox; it has a differentiated mechanism of action, a relatively high barrier to resistance and available evidence suggests it can be used in patients who have received the other approved smallpox antiviral treatment.   By year-end, Chimerix expects to complete initial TEMBEXA drug product manufacturing in order to satisfy a potential procurement contract to support national preparedness in the United States. Imipridones and ONC201 Chimerix’s acquisition of Oncoceutics, Inc., expands the Company’s oncology franchise with a late-stage, novel class of small molecule anti-cancer compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce tumor cell death in multiple cancer types. The BICR of radiographic imaging will enable clinical efficacy analyses of the first 50 patients with recurrent H3-K27M-mutant diffuse midline glioma who received single agent ONC201. These analyses will include overall response rate and key supportive endpoints, such as durability of response and other measures of clinical benefit. If favorable, these data may form the basis for an NDA submission seeking accelerated approval of ONC201 in the United States. In addition, a Phase 1 clinical trial for ONC206, our second imipridone product candidate, and IND-enabling work for our third imipridone candidate, ONC212, remain ongoing. DSTAT for AML Chimerix continues enrollment in the Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of DSTAT in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients. Chimerix expects to unblind data following enrollment of the first 80 evaluable patients in this study to assess complete response rates and minimal residual disease rates between the study arm and the control arm. This analysis is expected to take place in the second half of 2022. Expected 2021 Milestones Second Quarter 2021 Financial Results Chimerix reported a net loss of $17.8 million, or $0.21 per basic and diluted share, for the second quarter of 2021. During the same period in 2020, Chimerix recorded a net loss of $10.0 million, or $0.16 per basic and diluted share. Revenues for the second quarter of 2021 decreased to $0.4 million, compared to $1.4 million for the same period in 2020. Research and development expenses increased to $13.8 million for the second quarter of 2021, compared to $8.6 million for the same period in 2020. General and administrative expenses increased to $4.4 million for the second quarter of 2021, compared to $3.1 million for the same period in 2020.Chimerix's balance sheet at June 30, 2021, included approximately $140 million of capital available to fund operations, $14.0 million in a note payable related to the Oncoceutics transaction and approximately 86.2 million outstanding shares of common stock. Conference Call and Webcast Chimerix will host a conference call and live audio webcast to discuss second quarter 2021 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6658827. A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, . An archived webcast will be available on the Chimerix website approximately two hours after the event. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia. About TEMBEXA TEMBEXA is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals. TEMBEXA (brincidofovir) is a nucleotide analog lipid-conjugate designed to mimic a natural monoacyl phospholipid to achieve effective intracellular concentrations of the active antiviral metabolite, cidofovir diphosphate. Cidofovir diphosphate exerts its orthopoxvirus antiviral effects by acting as an alternate substrate inhibitor for viral DNA synthesis mediated by viral DNA polymerase. IMPORTANT SAFETY INFORMATION Including BOXED WARNING WARNINGS AND PRECAUTIONS Elevations in Hepatic Transaminases and Bilirubin: May cause increases in serum transaminases (ALT or AST) and serum bilirubin. Monitor liver laboratory parameters before and during treatment. Diarrhea and Other Gastrointestinal Adverse Events: Diarrhea and additional gastrointestinal adverse events including nausea, vomiting, and abdominal pain may occur. Monitor patients, provide supportive care, and if necessary, do not give the second and final dose of TEMBEXA. Coadministration with Related Products: TEMBEXA should not be co-administered with intravenous cidofovir. Carcinogenicity: TEMBEXA is considered a potential human carcinogen. Do not crush or divide TEMBEXA tablets and avoid direct contact with broken or crushed tablets or oral suspension. Male Infertility: Based on testicular toxicity in animal studies, TEMBEXA may irreversibly impair fertility in individuals of reproductive potential. ADVERSE REACTIONS Common adverse reactions (adverse events assessed as causally related by the investigator in ≥ 2% of subjects) experienced in the first 2 weeks of dosing with TEMBEXA were diarrhea, nausea, vomiting and abdominal pain. USE IN SPECIFIC POPULATIONS Pregnancy Based on findings from animal reproduction studies, TEMBEXA may cause fetal harm when administered to pregnant individuals. Pregnancy testing should be performed before initiation of TEMBEXA in individuals of childbearing potential to inform risk. An alternative therapy should be used to treat smallpox during pregnancy, if feasible. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the status of Chimerix’s oncology programs, and the potential benefits and government procurement of TEMBEXA. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current clinical study data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; the ability to generate positive results in a Phase 3 study in acute myeloid leukemia and subsequent approval for DSTAT; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT:Investor Relations:        Michelle LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor Relations212-362-1200will@sternir.com